Roche Receives CE Mark for Elecsys Cancer Test

Roche has received CE mark certification for its Elecsys anti-p53 immunoassay, a test used to diagnose various types of cancer.

The Elecsys test is used for the in vitro quantitative determination of anti-p53 antibodies in patients to aid physicians in diagnosis of esophageal cancer, bowel cancer and breast cancer.

Screening for anti-p53 antibodies can help to diagnose cancer earlier, increasing the chances that a patient responds to treatment. It can also help to monitor cancer cells that persist in patients after treatment.